Byetta, Januvia/Janumet and Victoza

As we have previously reported, safety concerns regarding incretin mimetics such Byetta, Januvia/Janumet and Victoza, have lead to hundreds of lawsuits being filed across the country. Reports suggest that people taking the medications, Januvia and/or Byetta, for the treatment of Type 2 diabetes may be at an increased risk to develop pancreatitis or pancreatic cancer.

As we have previously reported, research has shown that several incretin mimetic pharmaceuticals may cause substantial injury in Type II diabetes patients. Incretin mimetic drugs help regulate blood sugar by stimulating insulin production by the pancreas.

 The April 8, 2013, edition of the Journal of the American Medical Association Internal Medicine (“JAMA”) published a

As we have previously reported, research has shown that several incretin mimetic pharmaceuticals, such as Byetta, Januvia/Janumet and Victoza, may cause substantial injury in Type II diabetes patients. Incretin mimetic drugs help regulate blood sugar by stimulating insulin production by the pancreas.

Doctors have expressed concern about these drugs and their connection between pancreatitis,

As we have previously reported, litigation regarding incretin mimetics, such as Byetta, Januvia/Janumet and Victoza, continues to grow across the country. Byetta (Exenatide), manufactured by Amylin Pharmaceuticals, in association with Eli Lilly and Co., entered the market in 2005 for the treatment of Type 2 diabetes.  Byetta, now sold by Bristol-Myers Squibb

Researchers at Johns Hopkins University have recently determined that a number of incretin mimetic diabetes medications like Byetta, Januvia/Janumet and Victoza could be linked to pancreatitis and pancreatic cancer.

A motion to consolidate the incretin mimetic cases into one MDL is currently pending. The Judicial Panel on Multidistrict Litigation (JPML) will likely hear oral argument,

There are an estimated 25 million people in the United States with diabetes with an estimated $245 billion a year in diabetes-related health costs.  A number of drugs have been introduced to treat diabetes patients and time has shown that certain types of these drugs can cause substantial injury.

Byetta (Exenatide), manufactured by Amylin Pharmaceuticals